4D Molecular Therapeutics

FDMT60

$12.82arrow_drop_down23.78%-$4.00

FDMT60

$12.82

arrow_drop_down23.78%-$4.00

Performance History

Key Stats
Open	$16.23
Prev. Close	$16.16
EPS	-2.24
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	16.08	17.21
52 Week Range	9.44	36.25

Ratios







EPS	-2.24

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About 4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) is a revolutionary biotechnology company focused on developing gene therapies using its proprietary Therapeutic Vector Evolution platform. The company's approach combines the power of gene therapy with the precision of molecular targeting to deliver transformative treatments for patients with severe genetic diseases. FDMT's innovative platform allows for the engineering of next-generation viral vectors that can efficiently and selectively deliver therapeutic genes to specific target tissues. This targeted delivery system maximizes the therapeutic benefit while minimizing off-target effects and immune responses.

FDMT's stock price history has shown impressive growth since the company's inception. The company has consistently delivered strong financial results and achieved significant milestones, which has driven investor confidence and contributed to the stock's upward trajectory. The stock's performance reflects the market's recognition of FDMT's potential to revolutionize the field of gene therapy and address significant unmet medical needs.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Headquarters: EmeryVille
Employees: 137
Exchange: NASDAQ

add 4D Molecular Therapeutics to watchlist

Keep an eye on 4D Molecular Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is 4D Molecular Therapeutics's (FDMT) price per share?

The current price per share for 4D Molecular Therapeutics (FDMT) is $12.82. The stock has seen a price change of -$4 recently, indicating a -23.78% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for 4D Molecular Therapeutics (FDMT)?

For 4D Molecular Therapeutics (FDMT), the 52-week high is $36.25, which is 182.76% from the current price. The 52-week low is $9.44, the current price is 35.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is 4D Molecular Therapeutics (FDMT) a growth stock?

4D Molecular Therapeutics (FDMT) has shown an average price growth of 0.41% over the past three years. It has received a score of 66 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying 4D Molecular Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is 4D Molecular Therapeutics (FDMT) stock price performance year to date (YTD)?

As of the latest data, 4D Molecular Therapeutics (FDMT) has a year-to-date price change of -39.67%. Over the past month, the stock has experienced a price change of -12.85%. Over the last three months, the change has been -43.72%. Over the past six months, the figure is -58.69%.

help

Is 4D Molecular Therapeutics (FDMT) a profitable company?

4D Molecular Therapeutics (FDMT) has a net income of -$100.84M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 72.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -849.12K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $20.72M, although specific revenue growth data is currently not available. The gross profit is $14.97M. Operating income is noted at -$112.87M. Furthermore, the EBITDA is -$126.76M.

help

What is the market capitalization of 4D Molecular Therapeutics (FDMT)?

4D Molecular Therapeutics (FDMT) has a market capitalization of $856.46M. The average daily trading volume is 635.37K, indicating the stock's liquidity and investor engagement.